Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein
Bernstein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $441 from $506 and keeps a Market Perform ...
Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...
Cautious Optimism for Vertex Pharmaceuticals: Suzetrigene’s Potential Amidst Placebo ...
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
Cautious Outlook on Vertex Pharmaceuticals Due to Suzetrigine’s Uncertain Efficacy in DPN ...
William Pickering, an analyst from Bernstein, reiterated the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated ...
Vertex Pharmaceuticals宣布ALYFTREK获得FDA批准
这一消息直接来自Vertex Pharmaceuticals Incorporated，报告的签署人是公司执行副总裁兼首席法务官Jonathan Biller。FDA对ALYFTREK的批准是Vertex Pharmaceuticals的一个重要进展，可能会加强公司在囊性纤维化治疗领域的产品组合。
Cramer’s Mad Dash: Vertex Pharmaceuticals
CNBC’s Jim Cramer delivers his daily Mad Dash. Georgia appeals court removes Fani Willis from Trump 2020 election case Chip ...
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...
Vertex's painkiller results match placebo in study, shares tumble
Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...
来自MSN13 小时
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...
Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market
Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.16% higher to $397.27 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.09% ...